VyantBioInc_OTC_VYNT_202210-K.pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM 10-K (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,2022 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT O

2、F 1934 For the transition period from to Commission file number 001-35817 VYANT BIO,INC.(Exact name of registrant as specified in its charter)Delaware 04-3462475(State or other jurisdictionof incorporation or organization)(I.R.S.EmployerIdentification No.)2 Executive Campus2370 State Route 70,Suite

3、310Cherry Hill,NJ 08002(201)479-1357(Address,including zip code,and telephone number,including area code,of registrants principal executive offices)Securities registered pursuant to Section 12(b)of the Act:Title of each class Trading Symbol Name of each exchange on which registeredCommon Stock,$0.00

4、01 par value per share VYNT The Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g)of the Act:None Indicate by check if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to f

5、ile reports pursuant to Section 13 or Section 15(d)of the Act.Yes:No:Indicate by check mark if the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the SecuritiesExchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was re

6、quired to file suchreports),and(2)has been subject to such filing requirements for the past 90 days.Yes:No:Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T during the preceding 12 mon